Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 96

Similar articles for PubMed (Select 23340036)

1.

Antihypertensive therapy in hypertrophic cardiomyopathy.

Argulian E, Messerli FH, Aziz EF, Winson G, Agarwal V, Kaddaha F, Kim B, Sherrid MV.

Am J Cardiol. 2013 Apr 1;111(7):1040-5. doi: 10.1016/j.amjcard.2012.12.026. Epub 2013 Jan 19.

PMID:
23340036
2.

Timing and significance of exercise-induced left ventricular outflow tract pressure gradients in hypertrophic cardiomyopathy.

Nistri S, Olivotto I, Maron MS, Grifoni C, Baldini K, Baldi M, Sgalambro A, Cecchi F, Maron BJ.

Am J Cardiol. 2010 Nov 1;106(9):1301-6. doi: 10.1016/j.amjcard.2010.06.057. Epub 2010 Sep 21.

PMID:
21029828
3.

Long-term follow-up after percutaneous septal ablation in hypertrophic obstructive cardiomyopathy.

Seggewiss H, Rigopoulos A, Welge D, Ziemssen P, Faber L.

Clin Res Cardiol. 2007 Dec;96(12):856-63. Epub 2007 Sep 27.

PMID:
17891517
4.

Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy.

Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, Cecchi F, Maron BJ.

N Engl J Med. 2003 Jan 23;348(4):295-303.

5.

One-year follow-up of percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy in 312 patients: predictors of hemodynamic and clinical response.

Faber L, Welge D, Fassbender D, Schmidt HK, Horstkotte D, Seggewiss H.

Clin Res Cardiol. 2007 Dec;96(12):864-73. Epub 2007 Sep 25.

PMID:
17891518
6.

Salutary effect of disopyramide on left ventricular diastolic function in hypertrophic obstructive cardiomyopathy.

Matsubara H, Nakatani S, Nagata S, Ishikura F, Katagiri Y, Ohe T, Miyatake K.

J Am Coll Cardiol. 1995 Sep;26(3):768-75.

7.

Provocation of latent left ventricular outflow tract gradients with amyl nitrite and exercise in hypertrophic cardiomyopathy.

Marwick TH, Nakatani S, Haluska B, Thomas JD, Lever HM.

Am J Cardiol. 1995 Apr 15;75(12):805-9.

PMID:
7717284
8.

Left ventricular outflow tract gradient decrease with non-surgical myocardial reduction improves exercise capacity in patients with hypertrophic obstructive cardiomyopathy.

Ruzyłło W, Chojnowska L, Demkow M, Witkowski A, Kuśmierczyk-Droszcz B, Piotrowski W, Rausinska L, Karcz M, Małecka L, Rydlewska-Sadowska W.

Eur Heart J. 2000 May;21(9):770-7.

9.

Long-term effects of dual chamber pacing in patients with hypertrophic cardiomyopathy without outflow tract obstruction at rest.

Gadler F, Linde C, Juhlin-Dannfelt A, Ribeiro A, Rydén L.

Eur Heart J. 1997 Apr;18(4):636-42.

10.

[Hypertrophic cardiomyopathy with left ventricular dynamic obstruction syndrome in hypertensive adult patients].

Brandt CM, Boulenc JM, Carrière T, Verdun A, Imbs JL.

Presse Med. 1991 Nov 23;20(39):1923-6. French.

PMID:
1837084
11.

β Blockers for prevention of exercise-induced left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy.

Nistri S, Olivotto I, Maron MS, Ferrantini C, Coppini R, Grifoni C, Baldini K, Sgalambro A, Cecchi F, Maron BJ.

Am J Cardiol. 2012 Sep 1;110(5):715-9. doi: 10.1016/j.amjcard.2012.04.051. Epub 2012 May 24.

PMID:
22633205
12.

Altered autonomic cardiac control in hypertrophic cardiomyopathy. Role of outflow tract obstruction and myocardial hypertrophy.

Limbruno U, Strata G, Zucchi R, Baglini R, Mengozzi G, Balbarini A, Mariani M.

Eur Heart J. 1998 Jan;19(1):146-53.

13.

Effect of obstruction on longitudinal left ventricular shortening in hypertrophic cardiomyopathy.

Barac I, Upadya S, Pilchik R, Winson G, Passick M, Chaudhry FA, Sherrid MV.

J Am Coll Cardiol. 2007 Mar 20;49(11):1203-11. Epub 2007 Mar 6.

14.

Beta-blocker therapy for dynamic left ventricular outflow tract obstruction induced by exercise.

Cabrera-Bueno F, García-Pinilla JM, Gómez-Doblas JJ, Montiel-Trujillo A, Rodríguez-Bailón I, de Teresa-Galván E.

Int J Cardiol. 2007 Apr 25;117(2):222-6. Epub 2006 Jul 17.

PMID:
16844244
15.

Comparison of Valsalva manoeuvre and exercise in echocardiographic evaluation of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy.

Jensen MK, Havndrup O, Pecini R, Dalsgaard M, Hassager C, Helqvist S, Kelbæk H, Jørgensen E, Køber L, Bundgaard H.

Eur J Echocardiogr. 2010 Oct;11(9):763-9. doi: 10.1093/ejechocard/jeq063. Epub 2010 May 15.

16.
17.

The frequency and functional impact of overlapping hypertension on hypertrophic cardiomyopathy: a single-center experience.

Aslam F, Haque A, Foody J, Shirani J.

J Clin Hypertens (Greenwich). 2010 Apr;12(4):240-5. doi: 10.1111/j.1751-7176.2009.00251.x.

PMID:
20433544
19.

Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: one-year follow-up.

Lakkis NM, Nagueh SF, Dunn JK, Killip D, Spencer WH 3rd.

J Am Coll Cardiol. 2000 Sep;36(3):852-5.

20.

Oral disopyramide therapy for obstructive hypertrophic cardiomyopathy.

Sherrid M, Delia E, Dwyer E.

Am J Cardiol. 1988 Nov 15;62(16):1085-8.

PMID:
3189171
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk